Shares of Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) hit a new 52-week low during mid-day trading on Monday. The stock traded as low as GBX 28 and last traded at GBX 29.83, with a volume of 64,571 shares. The stock had previously closed at GBX 29.90.
Faron Pharmaceuticals Oy Price Performance
The stock has a 50-day moving average price of GBX 34.62 and a 200 day moving average price of GBX 49.43. The company has a debt-to-equity ratio of 154.15, a current ratio of 2.40 and a quick ratio of 1.09. The firm has a market cap of £66.95 million, a price-to-earnings ratio of -2.87 and a beta of 1.12.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
See Also
- Five stocks we like better than Faron Pharmaceuticals Oy
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
